Skip to main content

Parkinson's Disease Progression

Antisense Oligonucleotide Treatment Shows Promise in Treating Parkinson's Disease Progression



Parkinson’s disease (PD), as well as many other neurodegenerative disorders, has shown a link between the abnormal aggregation of a protein called α-synuclein (aSyn) and neuronal death. These aggregates, known as Lewy bodies and Lewy neurites depending on their subcellular localization, can spread by continuously causing normal endogenous aSyn to misfold. The complex nature of this aggregation process poses significant challenges in disease management. Now, promising research from scientists in Japan suggests potential breakthroughs in developing effective treatment strategies for PD.

In a study published in Volume 12, Issue 75 of the journal Acta Neuropathologica Communications on May 14, 2024, a research team from Tokyo Medical and Dental University (TMDU) explored the use of antisense oligonucleotides (ASOs) to reduce the expression of aSyn and improve symptoms in a mouse model of PD.

ASOs are compounds that can be engineered to induce the target mRNA-specific degradation, which in turn decreases the levels of its corresponding protein. Even though they are not the only drugs that can control the expression of aSyn, ASOs have a crucial advantage over other approaches, as lead author Professor Tetsuya Nagata explains: “Currently, antibody drugs and vaccines targeting aSyn are under development for aSyn-related neuropathies, but their effects may not prevent the disease from progressing inside cells. In contrast, nucleic acid drugs like ASOs that specifically control intracellular levels of normal aSyn, while also suppressing pathogenic aSyn propagation, could offer higher safety and efficacy by both retaining the natural physiological functions of the protein while inhibiting the spread of pathogenic aSyn.”

Considering that PD often emerges and then spreads out from specific regions in the brain, the researchers tested whether administering ASOs locally at diseased sites could be a sound treatment or preventive strategy. To this end, they injected ASOs directly into either the left or right striatum (a critical component of the motor and reward systems) of mice brain and analyzed the spread of aSyn pathologies throughout various brain regions using the presence of Lewy body-like and Lewy neurite-like pathologies as indicators.

When ASOs were injected into the left striatum two weeks before inoculation of the mice’s brain with disease-causing fibrils at the same site, a significant decrease of over 90% in Lewy pathology-like neuronal inclusion was observed. Compared to the control group, this pre-treatment effectively prevented the spread of abnormal fibrils-induced aggregate towards multiple regions of the brain. Even when ASOs were administered at the same time or even after inoculation with fibrillar aSyn, there was a notable inhibitory effect in the left striatum and other areas of the brain.

The researchers also tested whether the administration of ASOs at locations distant from the initial disease site would protect other brain regions. Accordingly, they injected ASOs in the right stratum two weeks before inoculation at the left striatum and visualized pathologic aSyn aggregates via immunostaining. Interestingly, this approach worked well as the density of these aSyn aggregates was much lower in the right striatum and right motor cortex near the SO administration site.

Together, the results of this study suggest that ASO-based treatments are worth pursuing in our strife against neurodegenerative disorders. “For the first time, we demonstrated in vivo that suppressing aSyn expression can inhibit the progression of pathology from Lewy neurites to Lewy bodies, with some of these effects being reversible,” highlights another author Professor Takanori Yokota. “We also observed the inhibitory effect of ASO on pathology progression in regions distant from the injection site of fibrous aSyn. This suggests the potential for treating PD, dementia with Lewy bodies, multiple system atrophy, and other aSyn-based diseases at various stages by reducing endogenous aSyn via ASOs without completely depleting this vital protein.”

We certainly hope these findings will put us one step closer to preventing PD and similar diseases right on their tracks.

Protective effects of antisense oligonucleotides (ASOs) targeting Snca mRNA

Researchers from Japan investigated how ASOs administered locally into the brains of mice models for Parkinson’s disease can help prevent the formation and spread of harmful aSyn aggregates through different regions. Their findings show ASOs could be a promoting therapeutic strategy to both prevent and control the progression of various neurodegenerative diseases.

Many neurodegenerative diseases are caused by the aggregation of α-synuclein (aSyn) into abnormal fibril structures, which then spread throughout the brain, damaging neurons. In a recent study, researchers from Japan explored an emerging treatment strategy involving antisense oligonucleotides (ASOs), which can be tailored to control the levels of aSyn produced by neurons. They found that, by locally administering ASOs to specific regions of the brain, they could prevent the accumulation and spread of fibrils.

Neurodegeneration, dopamine, substantia nigra, tremor, bradykinesia, rigidity, postural instability, Lewy bodies, alpha-synuclein, deep brain stimulation, motor symptoms, non-motor symptoms, genetic factors, environmental triggers, neuroinflammation, oxidative stress, mitochondrial dysfunction, Parkinsonism, L-DOPA, movement disorder,

#ParkinsonsDisease, #Neurodegeneration, #Dopamine, #Tremor, #Bradykinesia, #Rigidity, #LewyBodies, #AlphaSynuclein, #DeepBrainStimulation, #MotorSymptoms, #NonMotorSymptoms, #Neuroinflammation, #OxidativeStress, #MitochondrialDysfunction, #MovementDisorder, #L_DOPA, #BrainHealth, #Neurology, #Neuroscience, #MedicalResearch

International Conference on Genetics and Genomics of Diseases

Visit: genetics-conferences.healthcarek.com

Award Nomination: genetics-conferences.healthcarek.com/award-nomination/?ecategory=Awards&rcategory=Awardee

Award registration: genetics-conferences.healthcarek.com/award-registration/

For Enquiries: contact@healthcarek.com

Get Connected Here
---------------------------------
---------------------------------
in.pinterest.com/Dorita0211
twitter.com/Dorita_02_11_
facebook.com/profile.php?id=61555903296992
instagram.com/p/C4ukfcOsK36
genetics-awards.blogspot.com/
youtube.com/@GeneticsHealthcare

Comments

Post a Comment

Popular posts from this blog

Genetics role in ovarian cancer

The Medical Minute: Genetics play big role in ovarian cancer In 2024, about 19,680 women in the United States will receive a new diagnosis of ovarian cancer and 12,740 women will die from the disease, said Dr. Shaina Bruce , a gynecologic oncologist at Penn State Cancer Institute . The median age of all patients who develop ovarian cancer is 63. Historically, women at increased risk for ovarian cancer are recommended to have their fallopian tubes and ovaries removed when they have completed having children. Taking that step to protect themselves comes at a heavy price ― surgical menopause. But Bruce said medical science is catching up with ovarian cancer. Studies could lead to new methods for preventative care and the surgery needed to lower risk may be easier than it once was. Below, during Gynecologic Cancer Awareness Month, Bruce discusses the disease and why acting to reduce your risk is worth it. What’s the connection between heredity and ovarian cancer? About 25% of all cases of ...
Post a Comment
Read more

X chromosome

Gene on the X chromosome may help explain high multiple sclerosis rates in women Brain inflammation may be fueled by a gene on the X chromosome, a new study in mice suggests. And in female mice, who carry two X chromosomes, a diabetes drug called metformin may work to counteract that inflammation. If these findings bear out in later studies, they could help to unravel the long-standing mystery of why women, who have two copies of this inflammation-driving gene, are more prone to certain autoimmune diseases, particularly after menopause. A disparity between the sexes Our bodies are patrolled by immune cells that provide protection against bacteria and viruses, but sometimes, these defenses turn on us. In the autoimmune disorder multiple sclerosis (MS), for instance, the immune system attacks myelin, the fatty insulation surrounding the nerve fibers in the brain and spinal cord. This leads to symptoms such as muscle weakness and difficulty walking, as well issues with memory and thinking...
Post a Comment
Read more

Multifactorial Genetic Conditions

Multifactorial Genetic Conditions Multifactorial genetic conditions are disorders caused by the combined effects of multiple genes and environmental factors , rather than a single gene mutation . These conditions do not follow classic Mendelian inheritance patterns and instead result from complex gene–environment interactions . Factors such as lifestyle, nutrition, infections, stress, and exposure to toxins can significantly influence disease onset and severity in genetically susceptible individuals. Common examples include diabetes, cardiovascular diseases , neural tube defects, asthma, and many neuropsychiatric disorders. Understanding multifactorial inheritance is essential for risk prediction, preventive medicine, and personalized healthcare strategies. Multifactorial inheritance, polygenic traits, gene–environment interaction, complex diseases, genetic susceptibility, environmental risk factors, non-Mendelian inheritance, disease predisposition, polygenic risk score, precision ...
Post a Comment
Read more